



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Marina V. Backer et al.  
Serial No. : 09/872,712  
Filed : June 1, 2001  
For : MOLECULAR DELIVERY VEHICLE FOR DELIVERY  
OF SELECTED COMPOUNDS TO TARGETS  
  
Examiner :  
Attorney Docket : 102131-200  
Group Art Unit :  
Confirmation No. : 4250

\*\*\*\*\*

I hereby certify that this correspondence is being deposited  
with the United States Postal Service as First Class Mail in an  
envelope addressed to: Commissioner for Patents, Washington,  
D.C. 20231 on 9 AUGUST 2001.

By

Todd E. Garabedian  
Todd E. Garabedian, Ph.D.  
Registration No. 39,197  
Attorney for Applicants

\*\*\*\*\*

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES UNDER 37 CFR §1.821)

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In the above Notice mailed on July 13, 2001 (copy  
enclosed), it was indicated that no copy of the Sequence Listing  
in Computer Readable Form (CRF) was submitted with the

application, and that Applicants must make an initial submission of such CRF.

At the outset, Applicants submit that such CRF was filed with the above-identified patent application on June 1, 2001. Enclosed is a copy of the Return Postcard stamped by the USPTO indicating that the Sequence Listing (both paper and CRF copies) were included with the application papers. Additionally, the Application Transmittal Letter (copy attached), certifies that both the paper copy and CRF of the Sequence Listing was included in the application package filed June 1, 2001.

Nevertheless, in order to expedite prosecution of this application, Applicants herein enclose a substitute copy of the Sequence Listing in both paper and CRF forms. Applicants respectfully request that this substitute Sequence Listing be entered in the present application.


Applicants further state that the content of the sequence listing information recorded in computer readable form is identical to the written (paper) sequence listing, and, where applicable, contains no new matter as required by 37 CFR §1.821(e)-(g), 1.825(b), or 1.825(d).

If a telephone conference would aid in the continued prosecution of this application, the Examiner is invited and encouraged to contact Applicants' representative at the telephone number listed below.

Respectfully submitted,

MARINA V. BACKER ET AL.

By



Todd E. Garabedian, Ph.D.  
Registration No. 39,197  
Attorney for Applicants

WIGGIN & DANA  
One Century Tower  
New Haven, CT 06508  
Telephone: (203) 498-4400  
Fax: (203) 782-2889

Date: 9 AUGUST 2001